BEAUTI_fUL-Studie – Analyse der Studienergebnisse

Abstract

The results of the BEAUTI_fUL-Study presented at the ESC meeting in Munich last year showed the following:

The use of Ivabradine in patients with coronary heart disease and left-ventricular dysfunction in combination with beta-blockers is safe and beneficial as an adjunct to standard therapy. A heart rate ≥ 70 beats/minute is associated with an impaired prognosis regarding cardiovascular death, hospitalisation for heart failure, revascularization and for myocardial infarction, and also regarding the primary composite of cardiovascular death, non-fatal myocardial infarction and hospitalisation for heart failure. As a consequence, heart rate should be routinely assessed in daily practice and taken into account as an additional risk factor. In patients with an initial heart rate ≥ 70 beats/minute, Ivabradine significantly reduces the need for subsequent revascularizations and the number of myocardial infarctions. As an add-on to standard therapy, Ivabradine might exert additional prognostically relevant effects, which complement the known benefical effects on ischaemia-related symptoms in patients with a heart rate > 60 beats/minute.

Literatur

• 1 Wilhelmsen I, Berglund G, Elmfeldt D. et al . The multifactor primary prevention trial in Goteborg, Sweden.  Eur Heart J. 1986;  7 279-288
• 2 Palatini P, Casiglia E, Pauletto P. Relation between physical training and ambulatory blood pressure in stage I hypertensive subjects: results of the HARVEST trial.  Circulation. 1994;  90 2870-2872
• 3 Diaz A, Bourassa G M, Guertin M C, Tardif J C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.  Eur Heart J. 2005;  26 967-974
• 4 Hjalmarson A, Gilpin E, Kjekshus J. et al . Influence of heart rate on mortality after acute myocardial infarction.  Am J Cardiol. 1990;  65 547-553
• 5 Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure.  Eur Heart J. 1999;  1 (suppl H) H64-H69
• 6 Fox K, Borer J S, Camm A J. et al, for the Heart Rate Working Group . J Am Coll Cardiol. 2007;  50 823-830
• 7 Borer J S. Drug insight: I _f inhibitors as specific heart-rate-reducing agents.  Nat Clin Pract Cardiovasc Med. 2004;  1 103-109
• 8 Tardif J C, Ford I, Tendera M, Bourassa M G, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.  Eur Heart J. 2005;  26 2529-2536
• 9 Fox K, Ford I, Steg G, Tendera M, Ferrari R. on behalf of the BEAUTIFUL investigators . Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.  Lancet. 2008;  372 807-816
• 10 Fox K, Ford I, Steg G, Tendera M, Ferrari R. on behalf of the BEAUTIFUL investigators . Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.  Lancet. 2008;  372 817-821
• 11 Cerbai E, Sartiani L, DePaoli P. et al . The properties of the pacemaker current I(f) in human ventricular myocytes are modulated by cardiac disease.  J Mol Cell Cardiol. 2001;  33 441-448
• 12 Michels G, Brandt M C, Zagidullin N. et al . Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations.  Cardiovasc Res. 2008;  78 466-475
• 13 Heusch G, Skyschally A, Gres P. et al . Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine-protection beyond heart rate reduction.  Eur Heart J. 2008;  29 2265-2275
• 14 Fox K, Garcia M A, Ardissino D. et al . Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.  Eur Hear J. 2006;  27 1341-1382
• 15 Dickstein K, Cohen-Solal A, Filippatos G. et al . Guidelines for the diagnosis and treatment of acute and chronic heart failure: executive summary: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heartfailure 2008 of the European Society of Cardiology.  Eur Hear J. 2008;  29 2388-2442